Patent ID: 11905286
Assignee: ANTABIO SAS
Field: Organic fine chemistry (Chemistry)
Classification: CPC C | IPC A  C

Claim 15:
16. A combination according to claim 15 wherein:
(i) the antibiotic agent is a carbapenem antibiotic; or
(ii) the antibiotic agent is a carbapenem antibiotic and the carbapenem antibiotic is meropenem; or
(iii) the metallo-β-lactamase inhibitor is a compound of Formula (A) or a pharmaceutically acceptable salt thereof, , wherein
R1A is selected from H, R1b and —CH2OC(O)R1b, wherein R1b is selected from an unsubstituted C1 to C4 alkyl group and phenyl;, is a cyclic group selected from C6 to C10 aryl, 5- to 10-membered heteroaryl, and 4- to 10-membered carbocyclic and heterocyclic groups;
each R2A is independently selected from:
(i) halo or R8;
(ii) C1-3 alkyl, O(C1-3 alkyl), S(C1-3 alkyl), SO(C1-3 alkyl) or SO2(C1-3 alkyl), any of which may be substituted with 1, 2 or 3 halo substituents and/or one R8 substituent; and
(iii) NRaC(O)Rc, and NRaC(O)NRbRc, wherein each Ra and Rb is independently selected from hydrogen and unsubstituted C1-2 alkyl and each Rc is unsubstituted C1-2 alkyl;, and
each R8 is independently selected from CN, OH, —C(O)NR9R, —NRfRg, —NR10C(NR11)R12, —C(NR10)NR11R12, and —NR10C(NR11)NR12R13; wherein each of Rf and Rg is independently H or unsubstituted C1-2 alkyl;
m is 0, 1, 2 or 3
R3A is selected from hydrogen and a C1 to C3 alkyl group which is unsubstituted or is substituted with 1, 2 or 3 substituents selected from halogen, —OR10, and —NR10R11;
n is 0 or 1
ZA is a bond or is selected from —NR10C(O)—, —C(O)NR10—, —NR10C(O)NR11—, —NR10C(O)O—, —OC(O)NR10, —NR10C(O)S—, —SC(O)NR10, —NR10C(NR11)—, —C(NR10)NR11—, —NR10C(NR11)NR12—, —NR10C(N+R11R12)—, —C(N+R10R11)NR10—, —NR10C(N+R11R12)NR3—, —NR10C(NR11)O—, —OC(NR10)NR11, —NR10C(N+R11R12)O—, —OC(N+R10R11)NR12—, —NR10C(NR11)S—, —SC(NR10)NR11, —NR10C(N+R11R12)S—, —SC(N+R10R11)NR12—, —C(O)NR15—, —NR10C(O)NR15—, —OC(O)NR15, —SC(O)NR15, —C(NR10)NR15—, —NR10C(NR11)NR15, —C(N+R10R11)NR15—, —NR10C(N+R11R12)NR15—, —OC(NR10)NR15, —OC(N+R10R11)NR15—, —SC(NR10)NR15, and —SC(N+R10R11)NR15—,
LA is a bond or is selected from C1-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, C1-3 alkylene-(C3-6cycloalkylene)-C1-3 alkylene, C1-4 alkylene-(C3-6cycloalkylene) and (C3-6cycloalkylene)-C1-4 alkylene, wherein L is unsubstituted or is substituted with 1 or 2 substituents selected from halogen, —OR10, and —NR10R11; or L is
—C(R10)═N—;
XA is a bond or, when L is other than a bond or —C(R10)═N—, X is a bond or is selected from —NR10—, —O—, —NR10C(NR11)—, and —C(NR10)—;
p is 0 or 1;
R4A is selected from H, —CN and C1 to C3 alkyl which is unsubstituted or is substituted with 1, 2 or 3 substituents selected from halogen, —OR10,
—NR10R11, and —CN;
or R4A is joined together with R5A to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;

R5A is selected from H, —CN and C1 to C3 alkyl which is unsubstituted or is substituted with 1, 2 or 3 substituents selected from halogen, —OR10,
—NR10R11, and —CN;
or R5A is joined together with R4A to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;
or R5A is joined together with R6A to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;

R6A is selected from H, —CN and C1 to C3 alkyl which is unsubstituted or is substituted with 1, 2 or 3 substituents selected from halogen, —OR10,
—NR10R11, and —CN;
or R6A is joined together with R5A to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;
or R6A is joined together with R7A if present to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;

R7A if present is selected from H, —CN and C1 to C3 alkyl which is unsubstituted or is substituted with 1, 2 or 3 substituents selected from halogen, —OR10, —NR10R11, and —CN;
or R7A is joined together with R6A to form, together with the atoms to which they are attached, a 5- to 6-membered heterocyclic group comprising at least one saturated carbon atom in the ring, said heterocyclic group being unsubstituted or substituted with 1 or 2 substituents selected from unsubstituted C1 to C2 alkyl, halogen, —OR10, —NR10R11, and —CN;

each R10, R11, R12 and R13 is independently H or methyl;
each R15 is independently substituted C1 to C4 alkyl or unsubstituted C2 to C4 alkyl, wherein when R15 is a substituted alkyl group the alkyl group is substituted with 1, 2 or 3 substituents independently selected from halogen, CN, OR10 and —NR10R11.